BioStock: Lipum has included first RA patient

Lipum recently announced that the first patient with rheumatoid arthritis has been included and dosed in ongoing phase I clinical trial with SOL-116 in the Netherlands. Previously, only healthy subjects were included in the study, but now the first patient has received a dose of SOL-116 or placebo. To find out more, we contacted Lipum’s Clinical Project Leader, Agneta Wennerholm, who is involved in the design and project management of the study. 

Read the full article at biostock.se:

https://www.biostock.se/en/2024/03/lipum-has-included-first-ra-patient/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se